KalVista Pharmaceuticals, Inc. (KALV) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD 2016 - 2022

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
KalVista Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2016 to 2022.
  • KalVista Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$92.9 M, a 12.8% decline from 2021.
  • KalVista Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$82.3 M, a 78.1% decline from 2020.
  • KalVista Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$46.2 M, a 58.2% decline from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$92.9 M -$10.6 M -12.8% May 1, 2022 Apr 30, 2023 10-K 2023-07-10
2021 -$82.3 M -$36.1 M -78.1% May 1, 2021 Apr 30, 2022 10-K 2023-07-10
2020 -$46.2 M -$17 M -58.2% May 1, 2020 Apr 30, 2021 10-K 2023-07-10
2019 -$29.2 M -$8.55 M -41.3% May 1, 2019 Apr 30, 2020 10-K 2022-07-07
2018 -$20.7 M -$4.89 M -30.9% May 1, 2018 Apr 30, 2019 10-K 2021-07-13
2017 -$15.8 M +$2.8 M +15% May 1, 2017 Apr 30, 2018 10-K 2020-07-01
2016 -$18.6 M May 1, 2016 Apr 30, 2017 10-K 2019-07-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.